AntiCEA M3-I
Ontology highlight
ABSTRACT: Interventions: The trial will involve 20 adult patients with colorectal cancer, to be divided into 2 10-member groups for each dose level. One single intravenous dose of 0.3 or 1mg of fragment marked with 5-7 mCi of 131I will be administered, depending on the group.;Antibodies, Monoclonal;Radioimmunodetection;Iodine Radioisotopes;Injections, Intramuscular;131I-antiCEA M3
Primary outcome(s): Pharmaceutical safety, measuring time: 6 months.
Study Design: Allocation: Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Assignment: Other. Purpose: Diagnostic
DISEASE(S): Gastrointestinal Diseases,Gastrointestinal Neoplasms,Rectal Diseases,Intestinal Diseases,Colorectal Cancer,Digestive System Diseases,Colorectal Neoplasms,Intestinal Neoplasms,Digestive System Neoplasms,Colonic Diseases
PROVIDER: 2571384 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA